← Back to All Insights

The 510(k) pathway offers a faster route to market than De Novo or PMA—but only if your predicate device strategy is correct. A wrong choice doesn't just delay your submission by months. It can redirect your entire development program, add $2-8M in unexpected costs, and potentially kill the device before it reaches market.

Yet predicate strategy remains one of the least scrutinized areas in investor due diligence. Companies and investors treat it as a checkbox—identify a predicate, build the regulatory package, submit. The reality is far more complex, and the risks are far greater.

The Economics of Predicate Strategy Failure

When the FDA questions your predicate selection, you face three options:

Most companies discover the problem 6-12 months into a 510(k) submission process, after they've already spent significant resources. This timing is particularly destructive because it comes after Series A funding, when runway is precious and investor patience is limited.

Common Predicate Strategy Mistakes

Mistake #1: The Convenience Predicate

A company identifies a predicate solely because it exists and has a similar-sounding intended use—not because it's truly appropriate. Example: A surgical robot company chose a laparoscopic instrument predicate because both were used in "minimally invasive surgery," despite vastly different technologies and functions.

Result: FDA rejected the 510(k), citing fundamental differences in technology and control mechanisms. The company had to pivot to De Novo, adding 18 months and $3M to their timeline.

Mistake #2: The Obsolete Predicate

A diagnostic device company based their predicate on a device cleared in 2001. The predicate used outdated technology that the FDA itself had discouraged through subsequent guidance documents. The company assumed any legally-marketed device was acceptable as a predicate.

Result: The FDA issued a Complete Response Letter, stating that the predicate itself was now considered obsolete and that predicate creep had led to a device that didn't meet current clinical evidence standards. The company ultimately withdrew the 510(k) and pursued Breakthrough Device Designation.

Mistake #3: The Indication Mismatch

A wound care device company selected a predicate cleared for "minor wounds and abrasions" but intended to market for "complicated diabetic ulcers." The companies assumed the devices were similar enough, and broader indications would come later.

Result: The FDA noted that the predicate's narrow clearance didn't support the broader indication. The company would need to either (a) accept the predicate's narrow indication or (b) generate clinical data proving efficacy for the broader indication—which essentially meant a PMA-level evidence package.

Red Flags for Predicate Risk

Single Predicate Identified: If the company has identified only one predicate, they haven't done thorough predicate analysis. Best practice requires identifying 5-10 potential predicates and systematically eliminating those that don't fit.
Predicate Age > 10 Years: Predicates older than a decade face FDA skepticism about technological appropriateness. The FDA increasingly questions whether "predicate creep" has occurred—where a series of devices have gradually diverged from the original predicate technology.
FDA Warnings or Recalls on Predicate: If the predicate device has MDR issues, recalls, or warning letters, the FDA will scrutinize the 510(k) more carefully. You're essentially saying your device is equivalent to a device with known safety issues.
Predicate from Different Device Class: If your predicate is from Class I and you're seeking Class II clearance, or vice versa, you face classification risk. Class assignments often shift with new guidance, and classification is prerequisite to predicate selection.

Best Practices for Predicate Strategy

1. Conduct Comprehensive Predicate Landscape Analysis

Before settling on a predicate, your regulatory consultant should identify all potentially relevant predicates across the FDA PMDD (Premarket Medical Device Database). Analyze at least 5-10 candidates. For each, document: clearance date, indication, special conditions, and any post-market issues.

2. Engage FDA in Pre-Submission Meeting

A Pre-Sub meeting costs $5,000-10,000 but is invaluable for predicate validation. Present your proposed predicate and the data supporting substantial equivalence. Get FDA feedback on the predicate itself, not just your submission package. This is your chance to pivot before investing heavily.

3. Develop Backup Predicate Strategy

Identify a secondary predicate that could support your submission if the primary predicate is questioned. Understand the differences between predicates and what additional data each would require. Some companies develop submissions supporting two predicates simultaneously.

4. Separate Technology Assessment from Predicate Assessment

Just because your technology is novel doesn't mean a predicate exists. Some truly novel devices don't have appropriate predicates and require De Novo or PMA pathways. Founders sometimes resist this conclusion because it increases timeline, but denying reality wastes time and capital.

5. Link Predicate to Reimbursement Strategy

The predicate's intended use becomes your cleared indication, which shapes reimbursement coding and coverage policy. A predicate with narrow intended use might achieve fast FDA approval but face reimbursement barriers. Factor reimbursement strategy into predicate selection, not just regulatory timeline.

CDRH Annual Report Insights on Predicate Trends

FDA's Center for Devices and Radiological Health releases annual performance data showing predicate selection is becoming more scrutinized. In 2024, Additional Information Requests citing predicate concerns increased 18% year-over-year. This suggests FDA is more willing to challenge predicate selections, particularly for devices with novel technology components.

The report also shows that devices that engaged FDA in Pre-Sub meetings had 35% faster review times than those that didn't. Pre-Subs specifically addressing predicate strategy had the highest success rates.

The Strategic Perspective

Predicate strategy isn't primarily a regulatory question—it's a strategic business question. The predicate you choose determines not just your regulatory timeline, but your cleared indication, which shapes your entire go-to-market strategy, reimbursement approach, and competitive positioning.

Companies that treat predicate strategy as a critical business decision, not a regulatory checkbox, make faster progress to market and face fewer surprises. They engage regulatory experts early, don't rush to choose a predicate, and actively consider the full business implications of their choice.

Bottom Line

Predicate device strategy is a make-or-break decision that deserves serious analysis before you lock in your regulatory path. A wrong choice costs millions and months. A right choice opens a clear path to market. Investors and founders who treat this with appropriate rigor save themselves significant capital and timeline risk.

References

  1. FDA CDRH. "2024 Annual Performance Report: 510(k) Program Performance Data." fda.gov
  2. FDA CDRH. "Guidance for Industry and FDA Staff: The 510(k) Program—Evaluating Substantial Equivalence." December 2023. fda.gov
  3. FDA. "Predicate Device Selection in 510(k) Submissions: Best Practices." Draft Guidance, September 2023. fda.gov
  4. Covington & Burling LLP. "Challenges in 510(k) Predicate Selection: Recent FDA Trends and Strategic Considerations." Medical Device Law Alert, 2024. cov.com
  5. Emergo by UL. "Predicate Device Selection and Regulatory Pathway Optimization." White Paper, 2024. emergobyul.com